BCL2 and acute myeloid leukemia: Recent studies suggest that combinations of demethylating agents with the BCL2 apoptosis regulator (BCL2) antagonist venetoclax is very effective and well tolerated in AML; this stabilizing treatment can induce complete remission for a larger fraction of patients and may also be effective in patients with chemoresistant AML relapse [8,9].